Efficacy and tolerability of oral XXXX and @entity1288 / @entity1510 combination in opioid-na  ve @entity5 @entity1 : a propensity analysis.

@entity1 @entity390 @entity1288 @entity5 @entity1337 @entity391 @entity1510 @entity158 @entity1142 @entity16486
BACKGROUND: World Health Organization step III opioids are required to relieve moderate-to-severe @entity5 ; @entity1142 is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release @entity1288 / @entity1510 (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release @entity1288 ( @entity16486 ) alone to OXN in opioid-na  ve @entity5 @entity1 with moderate-to-severe @entity158 . METHODS: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. RESULTS: Out of the 210 @entity1 recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, @entity158 intensity decreased by    3 points after 60 days, indicating comparable analgesic efficacy. Responder rates were similar between groups. @entity1337 was achieved and maintained with similarly low and stable dosages over time (12.0-20.4 mg/d for @entity16486 and 11.5-22.0 mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30 days and 60 days in OXN recipients (-16, P<0.0001 and -3.5, P=0.02, respectively); BFI worsened in the @entity16486 group. The overall incidence of drug-related adverse events was 28.9% in the @entity16486 group and 8.2% in the OXN group (P<0.01); @entity390 and @entity391 were two to five times less frequent with OXN. Quality of life improved to a significantly greater extent in @entity1 receiving OXN compared to @entity16486 (increase in Short Form-36 physical component score of 7.1 points vs 3.2 points, respectively; P<0.001). CONCLUSION: In @entity1 with chronic @entity5 , OXN provided analgesic effectiveness that is similar to @entity16486 , with early and sustained benefits in tolerability. The relationship between responsiveness to OXN and clinical characteristics is currently being investigated.
